seglitide and pasireotide

seglitide has been researched along with pasireotide* in 1 studies

Other Studies

1 other study(ies) available for seglitide and pasireotide

Article	Year
A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. Journal of medicinal chemistry, 2003, Jun-05, Volume: 46, Issue:12 A rational drug design approach, capitalizing on structure-activity relationships and involving transposition of functional groups from somatotropin release inhibitory factor (SRIF) into a reduced size cyclohexapeptide template, has led to the discovery of SOM230 (25), a novel, stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1-sst5). SOM230 has potent, long-lasting inhibitory effects on growth hormone and insulin-like growth factor-1 release and is a promising development candidate currently under evaluation in phase I clinical trials. Topics: Animals; CHO Cells; COS Cells; Cricetinae; Drug Design; Humans; Ligands; Magnetic Resonance Spectroscopy; Molecular Mimicry; Oligopeptides; Peptides, Cyclic; Radioligand Assay; Receptors, Somatostatin; Somatostatin; Structure-Activity Relationship	2003

Article

Year

A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential.

Journal of medicinal chemistry, 2003, Jun-05, Volume: 46, Issue:12

A rational drug design approach, capitalizing on structure-activity relationships and involving transposition of functional groups from somatotropin release inhibitory factor (SRIF) into a reduced size cyclohexapeptide template, has led to the discovery of SOM230 (25), a novel, stable cyclohexapeptide somatostatin mimic that exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1-sst5). SOM230 has potent, long-lasting inhibitory effects on growth hormone and insulin-like growth factor-1 release and is a promising development candidate currently under evaluation in phase I clinical trials.

Topics: Animals; CHO Cells; COS Cells; Cricetinae; Drug Design; Humans; Ligands; Magnetic Resonance Spectroscopy; Molecular Mimicry; Oligopeptides; Peptides, Cyclic; Radioligand Assay; Receptors, Somatostatin; Somatostatin; Structure-Activity Relationship

2003